Succinic Semialdehyde Dehydrogenase Deficiency: Review of the Natural History Study.


Journal

Journal of child neurology
ISSN: 1708-8283
Titre abrégé: J Child Neurol
Pays: United States
ID NLM: 8606714

Informations de publication

Date de publication:
11 2021
Historique:
pubmed: 5 1 2021
medline: 15 3 2022
entrez: 4 1 2021
Statut: ppublish

Résumé

The SSADHD Natural History Study was initiated in 2019 to define the natural course and identify biomarkers correlating with severity. The study is conducted by 4 institutions: BCH (US clinical), WSU (bioanalytical core), USF (biostatistical core), and Heidelberg (iNTD), with support from the family advocacy group (SSADH Association). Recruitment goals were to study 20 patients on-site at BCH, 10 with iNTD, and 25 as a standard-of care cohort. At this half-way point of this longitudinal study, 28 subjects have been recruited (57% female, mean 9 years, range 18 months-40 years). Epilepsy is present in half and increases in incidence and severity, as do psychiatric symptoms, in adolescence and adulthood. The average Full Scale IQ (FSIQ) was 53 (Verbal score of 56, Non Verbal score of 49), and half scored as having ASD. Although there was no correlation between gene variant and phenotypic severity, there were extreme cases of lowest functioning in one individual and highest in another that may have genotype-phenotype correlation. The most common EEG finding was mild background slowing with rare epileptiform activity, whereas high-density EEG and magnetoencephalography showed reduction in the gamma frequency band consistent with GABAergic dysfunction. MR spectroscopy showed elevations in the GABA/NAA ratio in all regions studied with no crossover between subjects and controls. The SSADH Natural History Study is providing a unique opportunity to study the complex pathophysiology longitudinally and derive electrophysiologic, neuroimaging, and laboratory data for correlation and to serve as biomarkers for clinical trials and prognostic assessments in this ultra-rare inherited disorder of GABA metabolism.

Identifiants

pubmed: 33393837
doi: 10.1177/0883073820981262
pmc: PMC8254814
mid: NIHMS1650255
doi:

Substances chimiques

Succinate-Semialdehyde Dehydrogenase EC 1.2.1.24

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1153-1161

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD091142
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD090255
Pays : United States

Références

Ann Neurol. 2003;54 Suppl 6:S73-80
pubmed: 12891657
EMBO J. 2009 Apr 8;28(7):959-68
pubmed: 19300440
J Neurochem. 2002 Apr;81(1):71-9
pubmed: 12067239
JIMD Rep. 2016;30:81-87
pubmed: 27338723
Clin Chim Acta. 1983 Sep 15;133(1):33-42
pubmed: 6627675
Ann Clin Transl Neurol. 2018 Dec 03;6(1):114-120
pubmed: 30656189
Neurology. 2020 Nov 10;95(19):e2675-e2682
pubmed: 32887777
Nat Genet. 2001 Oct;29(2):212-6
pubmed: 11544478
Biol Psychiatry. 2003 Oct 1;54(7):763-8
pubmed: 14512218
Pediatr Neurol. 2016 May;58:113-5
pubmed: 27268762
Neurology. 2009 Aug 11;73(6):423-9
pubmed: 19667317
Neurology. 2015 Sep 8;85(10):861-5
pubmed: 26268900
Brain Dev. 2012 Feb;34(2):107-12
pubmed: 21612881
J Inherit Metab Dis. 2009 Jun;32(3):343-52
pubmed: 19172412
Pediatrics. 1997 Apr;99(4):567-74
pubmed: 9093300
Ann Neurol. 2006 Jan;59(1):42-52
pubmed: 16240371
Exp Neurol. 2008 May;211(1):11-3
pubmed: 18374334
Brain Res. 2006 May 23;1090(1):15-22
pubmed: 16647690
J Biol Chem. 1995 Jan 6;270(1):461-7
pubmed: 7814412
Neurology. 2012 Jul 3;79(1):47-54
pubmed: 22722631
J Pharmacol Exp Ther. 2002 Jul;302(1):180-7
pubmed: 12065715
Int J Biochem. 1992 Sep;24(9):1493-9
pubmed: 1426531
Exp Neurol. 2008 Apr;210(2):449-57
pubmed: 18199435
Neurology. 2003 May 13;60(9):1413-7
pubmed: 12743223
J Inherit Metab Dis. 2018 Jul;41(4):699-708
pubmed: 29460030
Neurology. 2014 Mar 18;82(11):940-4
pubmed: 24523482
Clin Chim Acta. 1981 Apr 9;111(2-3):169-78
pubmed: 7226548
Ann Clin Transl Neurol. 2015 Jun;2(6):699-706
pubmed: 26125044
Hum Mutat. 2003 Dec;22(6):442-50
pubmed: 14635103

Auteurs

Phillip L Pearl (PL)

Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Melissa L DiBacco (ML)

Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Christos Papadelis (C)

Jane and John Justin Neuroscience Center, Cook Children's Health Care System, Fort Worth, TX, USA.
Department of Pediatrics, TCU and UNTHSC School of Medicine, Fort Worth, TX, USA.
Laboratory of Children's Brain Dynamics, Division of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Thomas Opladen (T)

Department of Child Neurology and Metabolic Disorders, University Children's Hospital, Heidelberg, Germany.

Ellen Hanson (E)

Neurodevelopmental Core, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Jean-Baptiste Roullet (JB)

Department of Pharmacotherapy, Washington State University, Spokane, WA, USA.

K Michael Gibson (KM)

Department of Pharmacotherapy, Washington State University, Spokane, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH